JP6871587B2 - シアル酸誘導体、その製造方法及びそれを利用したシアリダーゼ阻害剤、抗菌剤、抗ウイルス剤 - Google Patents
シアル酸誘導体、その製造方法及びそれを利用したシアリダーゼ阻害剤、抗菌剤、抗ウイルス剤 Download PDFInfo
- Publication number
- JP6871587B2 JP6871587B2 JP2016162979A JP2016162979A JP6871587B2 JP 6871587 B2 JP6871587 B2 JP 6871587B2 JP 2016162979 A JP2016162979 A JP 2016162979A JP 2016162979 A JP2016162979 A JP 2016162979A JP 6871587 B2 JP6871587 B2 JP 6871587B2
- Authority
- JP
- Japan
- Prior art keywords
- sialic acid
- acid derivative
- group
- compounds
- sialidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical class CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims description 84
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000002911 sialidase inhibitor Substances 0.000 title claims description 10
- 239000003242 anti bacterial agent Substances 0.000 title claims description 6
- 239000003443 antiviral agent Substances 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 101
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 239000007800 oxidant agent Substances 0.000 claims description 13
- 150000001768 cations Chemical class 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- -1 sialic acid glycosides Chemical class 0.000 description 46
- 108010006232 Neuraminidase Proteins 0.000 description 40
- 102000005348 Neuraminidase Human genes 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- 241000193468 Clostridium perfringens Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 241001500351 Influenzavirus A Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006225 natural substrate Substances 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002168 ethanoic acid esters Chemical class 0.000 description 3
- 239000004210 ether based solvent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 150000003949 imides Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910052723 transition metal Inorganic materials 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 2
- 101000583741 Clostridium perfringens Sialidase Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 101000968491 Pseudomonas sp. (strain 109) Triacylglycerol lipase Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000010953 base metal Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052790 beryllium Inorganic materials 0.000 description 2
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003759 ester based solvent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 150000002357 guanidines Chemical class 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940061367 tamiflu Drugs 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- HQKDFKRGDIWHLX-CLFYSBASSA-N (z)-2-acetylsulfanylethoxyimino-(dimethylamino)-oxidoazanium Chemical compound CN(C)[N+](\[O-])=N\OCCSC(C)=O HQKDFKRGDIWHLX-CLFYSBASSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical group [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- JINJZWSZQKHCIP-UFGQHTETSA-N 2-deoxy-2,3-dehydro-N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO JINJZWSZQKHCIP-UFGQHTETSA-N 0.000 description 1
- NEGUMGNBGIFXAL-UHFFFAOYSA-N 3-methyl-3-(trifluoromethyl)dioxirane Chemical compound FC(F)(F)C1(C)OO1 NEGUMGNBGIFXAL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102220536188 DPH3 homolog_E116A_mutation Human genes 0.000 description 1
- 102220536173 DPH3 homolog_E116D_mutation Human genes 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102220507384 Gasdermin-C_R150K_mutation Human genes 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- JINJZWSZQKHCIP-UHFFFAOYSA-N Neu5Ac2en Natural products CC(=O)NC1C(O)C=C(C(O)=O)OC1C(O)C(O)CO JINJZWSZQKHCIP-UHFFFAOYSA-N 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102220539924 Nurim_R292K_mutation Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102220609944 Retinoschisin_D151A_mutation Human genes 0.000 description 1
- 102000040133 Sialidase family Human genes 0.000 description 1
- 108091059580 Sialidase family Proteins 0.000 description 1
- 102100028760 Sialidase-1 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KBGAYAKRZNYFFG-BOHATCBPSA-N aceneuramic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](NC(=O)C)[C@@H](O)[C@H](O)[C@H](O)CO KBGAYAKRZNYFFG-BOHATCBPSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- OZZOVSQSDIWNIP-UHFFFAOYSA-N acetic acid;azane Chemical compound [NH4+].[NH4+].CC([O-])=O.CC([O-])=O OZZOVSQSDIWNIP-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 102220388297 c.406C>A Human genes 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 150000008266 deoxy sugars Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003683 electrophilic halogenation reaction Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VUERQRKTYBIULR-UHFFFAOYSA-N fosetyl Chemical compound CCOP(O)=O VUERQRKTYBIULR-UHFFFAOYSA-N 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000002303 glucose derivatives Chemical group 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- GYCHYNMREWYSKH-UHFFFAOYSA-L iron(ii) bromide Chemical compound [Fe+2].[Br-].[Br-] GYCHYNMREWYSKH-UHFFFAOYSA-L 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- UKTIJASCFRNWCB-RMIBSVFLSA-N laninamivir octanoate hydrate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O UKTIJASCFRNWCB-RMIBSVFLSA-N 0.000 description 1
- 229950005327 laninamivir octanoate hydrate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- XXZNFWHGOMHWCO-UHFFFAOYSA-N n,n-diethylthiohydroxylamine Chemical compound CCN(S)CC XXZNFWHGOMHWCO-UHFFFAOYSA-N 0.000 description 1
- VBTQNRFWXBXZQR-UHFFFAOYSA-N n-bromoacetamide Chemical compound CC(=O)NBr VBTQNRFWXBXZQR-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- FHUOTRMCFQTSOA-UHFFFAOYSA-M potassium;acetic acid;acetate Chemical compound [K+].CC(O)=O.CC([O-])=O FHUOTRMCFQTSOA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229940061374 relenza Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102200017110 rs1137654 Human genes 0.000 description 1
- 102220163334 rs115335100 Human genes 0.000 description 1
- 102220006755 rs118192193 Human genes 0.000 description 1
- 102220069169 rs141903943 Human genes 0.000 description 1
- 102220204903 rs145905196 Human genes 0.000 description 1
- 102220050562 rs193920922 Human genes 0.000 description 1
- 102220166925 rs199522390 Human genes 0.000 description 1
- 102220036852 rs200872702 Human genes 0.000 description 1
- 102200003635 rs371195126 Human genes 0.000 description 1
- 102220028891 rs398123299 Human genes 0.000 description 1
- 102220064525 rs786205479 Human genes 0.000 description 1
- 102200122956 rs797045166 Human genes 0.000 description 1
- 102220101741 rs878854623 Human genes 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003865 secondary ammonium salts Chemical class 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003866 tertiary ammonium salts Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- UBZYKBZMAMTNKW-UHFFFAOYSA-J titanium tetrabromide Chemical compound Br[Ti](Br)(Br)Br UBZYKBZMAMTNKW-UHFFFAOYSA-J 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(1)一般式(I):
(2)一般式(II):
(3)前記(A)がスルホ基であることを特徴とする上記(1)又は(2)に記載のシアル酸誘導体。
(4)前記(B)がスルホ基であることを特徴とする上記(1)又は(2)に記載のシアル酸誘導体。
(5)上記(1)〜(4)のいずれか1項に記載のシアル酸誘導体を有効成分とすることを特徴とするシアリダーゼ阻害剤。
(6)(1)〜(4)のいずれか1項に記載のシアル酸誘導体を有効成分とすることを特徴とする抗菌剤。
(7)(1)〜(5)のいずれか1項に記載のシアル酸誘導体を有効成分とすることを特徴とする抗ウイルス剤。
(8)(1)又は(2)に記載のシアル酸誘導体の製造方法において、下記式(3a)1R、(3b)1S:
下記式(5a)1R、(5b)1S:
本発明における式(I)及び(II)に含まれる化合物は、以下に示す製造方法で合成することができる。図1に本発明に係るシアル酸誘導体の製造方法の一例を示す。
化合物(2a)(アセチル−4−アセタミド−3,6,7,8−テトラ−O−アセチル−2,4−ジデオキシ−β−D−グリセロ−D−ガラクト−オクトピラノシド)及び化合物(2b)(化合物2aのα−体)は公知の方法(例えば、非特許文献2)に従ってシアル酸から合成することができる。
本発明では、ヒドロキシ基が酢酸エステルとして保護された公知の化合物(2a)と(2b)を出発原料に用いるのが好ましいが、酢酸エステルの他に、ギ酸、クロロ酢酸、プロピオン酸、安息香酸などのエステルを保護基に用いることもできる。その他、トリエチルシリル基などのトリアルキルシリルエーテル系の保護基、ベンジル基やメトキシメチル基などのアルキルエーテル系の保護基、tert−ブトキシカルボニル基などカーバマート系の保護基を用いることもできるが、これらに限定されるものではない。
すなわち、下記式(3a)1R、(3b)1S:
下記式(5a)1R、(5b)1S:
化合物(2a)(アセチル=4−アセタミド−3,6,7,8−テトラ−O−アセチル−2,4−ジデオキシ−α−D−グリセロ−D−ガラクト−オクトピラノシド)及び化合物(2b)(化合物(2a)のβ−体)は公知の方法(例えば、非特許文献2)に従ってシアル酸から合成することができる。
化合物(2a)及び(2b)を約1:5のモル比で含む混合物(254mg,0.534mmol)を窒素雰囲気下で、蒸留した1,2−ジクロロエタン(6mL)に溶解し、約−10℃で氷冷した。次に、氷冷した混合溶液にチオ酢酸(0.227mL,3.22mmol)及びトリフルオロメタンスルホン酸トリメチルシリルエステル(0.581mL,3.21mmol)を加えてそのまま徐々に20℃に加温しながら反応が終了するまで20時間攪拌した。
(3b)(1S−アノマー:アキシアル位SAc基アノマー,CJV055401(=実験で得た物質につけた番号、以下同様)).Rf=0.4(EtOAc);1H−NMR(600MHz,CDCl3):1.91(1s,3H,NHAc),1.98−2.12(4s,12H,4OAc),2.15−2.19(ddd,1H,J2ax,1=1.6,J2ax,2eq=13.6,J2ax,3=5.1,H−2ax),2.30−2.36(m,1H,H−2eq),2.34(1s,3H,SAc),3.90−3.92(dd,1H,J5,4=10.4,J5,6=1.9,H−5),4.01−4.05(m,2H,H−4とH−8)4.26−4.29(dd,1H,J8',7=2.9,J8',8=12.6,H−8’),4.98−5.03(ddd,1H,J3,2eq=4.7,J=10.3,J=11.7,H−3),5.11−5.14(ddd,1H,J7,6=7.2,J7,8=6.3,J7,8'=2.9,H−7),5.30−5.32(dd,1H,J6,5=1.9,J6,7=7.2,H−6),5.40−5.42(d,1H,J=10,NH),6.13−6.14(d,1H,J1,2ax=4.7,H−1);+ESIHRMS計算値C20H29NNaO11S:514.1359,実測値:m/z514.1393[M+Na]+(150710−CJV031302).
(4b)(1S−アノマー:アキシアル位SAc基アノマー,CJV055401,CJV030702).Rf=0.4(EtOAc);1H−NMR(600MHz,CDCl3):1.99,2.02,2.10,2.13(4s,12H,(4a)c),2.36(1s,3H,SAc)3.84−3.86(dd,1H,J5,4=10,J5,6=1.8,H−5),4.10−4.13(m,1H,H−8),4.29−4.32(dd,1H,J8',8=12.6,J8',7=2.6,H−8’),4.48−4.51(t,1H,J4,3とJ4,5=9.7,H−4),5.19−5.22(ddd,1H,J7,6=7.8,J7,8=5.6,J7,8'=2.6H−7),5.31−5.33(dd,1H,J6,5=1.8,J6,7=7.8,H−6),5.52−5.54(d,1H,JNH,4=9.4Hz,NH)5.80(s,2H,H−2,H−3)6.27(s,1H,H−1);+ESIHRMS計算値C18H25NNaO9S:454.1148,実測値:m/z454.1177[M+Na]+(150710−CJV031302).
(3a)及び(3b)並びに(4a)及び(4b)の混合物.主成分の13C−NMRピーク(150MHz,CDCl3,CJV055401):20.67,20.70,20.91,21.06,23.16と23.34(CH3COO,CH3CONHとCH3COS),31.19,36.13,43.55,50.10,62.05,62.07,67.3467.37,69.26,69.60,69.86,72.45,78.66と79.01(C−1〜C−8),125.62と131.15((4a)と(4b)のC−2とC−3),169.41,169.56,169.79,170.00,170.48,170.50と170.97(CH3COOとCH3CONH),191.40と192.82(CH3COS);
(3a)及び(3b)並びに(4a)及び(4b)の混合物.副成分の13C−NMRピーク(150MHz,CDCl3,CJV055401):20.45,20.71,20.73,20.76,20.85,23.11,23.18と23.29(CH3COO,CH3CONHとCH3COS),30.55,30.58,30.75,33.01,35.47,43.17,48.24,49.13,61.37,67.28,67.73,68.26,70.06,70.14,70.24,71.89と76.17(C−1〜C−8),91.18,126.89と130.62((4a)と(4b)のC−2とC−3),167.82,168.97,169.35,169.41,169.56,169.72,169.86,170.12,170.15,170.24,170.54と170.86(CH3COOとCH3CONH),192.14と192.75(CH3COS).
CJV055401は約15%の1,7−ラクトン環化体(5−アセタミド−2,4,8,9−テトラ−O−アセチル−β−D−グリセロ−D−ガラクト−2−ノヌロピラノソン−7−オリド)を含む:13C−NMR(150MHz,CDCl3,CJV045301):20.47,20.74,20.76,20.79,20.95と23.19(CH3COO,CH3CONHとCH3COS),30.91,33.05,48.23,61.39,67.67,70.31,71.94と76.18(C−2〜C−8),91.18,91.35,164.42,167.86,169.01,169.33,169.78,170.59(CH3COOとCH3CONH).
前記で得られた化合物(3a)及び(3b)並びに化合物(4a)及び(4b)のモル比で約16:30:1:34の混合物(854mg、約1.8mmol)の酢酸(12mL)溶液に、酢酸アンモニウム(約1g、約13mmol、約7.8当量)とオキソン(登録商標)(3.67g、11.9mmol、7.17当量)を加えて20℃で約19時間攪拌した。次に、得られた反応液にメタノール(約10mL)を加えて、不溶物をセライトを用いて濾過し、濾液を減圧濃縮した。そして、残渣をシリカゲル(12.6g)を用いたカラムクロマトグラフィーで精製(溶出液は酢酸エチルとエタノールの割合を順次変化させた)し、油状物質として化合物(5a)及び(5b)並びに化合物(6b)(525mg)をモル比で約2:5.6:1の混合物として得た。
(5a)(1R−アノマー:エクアトリアルスルホナート).Rf=0.39(EtOAc:EtOH=2:1);1H−NMR(400MHz,CD3OD,CJV043403):1.8−2.0(m,1H,H−2ax)1.85(s,1H,NAc),1.97−2.08(4s,12H,4OAc),2.46−2.51(ddd,1H,J2eq,1=2.1,J2eq,2ax=12.6,J2eq,3=5.1,H−2eq),3.79−3.83(dd,1H,J5,4=10.4,J5,6=2.3,H−5),3.93−4.00(q,1H,J4,3=10.4,J4,5=10.4,H−4),4.19−4.25(dd,1H,J8,7=12.3,J8,8'=6.3,H−8)4.24−4.28(dd,1H,J1,2ax=11.8,J1,2eq=2.1,H−1),4.51−4.55(dd,1H,J8',7=2.8,J8',8=12.4,H−8’),4.96−5.03(ddd,1H,J3,2ax=11.3,J3,2eq=5.1,J3,4=10.2,H−3),5.28−5.32(td,1H,J7,6=6.2,J7,8=6.2,J7,8'=2.7,H−7),5.38−5.41(m,1H,H−6);−ESIHRMS計算値C18H26NO13S-:496.1130,実測値:m/z496.1142[M−H]-(160212−CJV051301).
(5b)(1S−アノマー:アキシアルスルホナート).Rf=0.4(EtOAc:EtOH=2:1);1H−NMR(600MHz,CD3OD,CJV060501):1.84(s,3H,NAc)1.9−2.1(m,1H,H2ax),1.97,2.00,2.07と2.08(4s,12H,4OAc),2.66−2.70(ddd,1H,J2eq,1=1,J2eq,2ax=13.9,J2eq,3=5.4H−2eq),3.94−3.97(t,1H,J4,3=10.3,J4,5=10.3,H−4),4.11−4.14(dd,1H,J8,7=5.3,J8,8'=12.6,H−8),4.41−4.43(dd,1H,J8',7=2.9,J8',8=12.3,H−8’),4.65−4.67(dd,1H,J1,2ax=6.7,H−1),4.76−4.78(dd,1H,J5,4=10.4,J5,6=2.2,H−5),5.20−5.22(ddd,1H,J7,6=7.8,J7,8=5.1,J7,8'=2.6,H−7),5.39−5.40(dd,1H,J6,5=2.2,J6,7=7.8,H−6),5.55−5.60(td,1H,J3,2ax=10.5,J3,2eq=5.4,J3,4=10.5,H−3);13C−NMR(150MHz,CDCl3):20.69,20.83,20.87,21.29と22.63(CH3COOとCH3CONH),31.45(C−2),50.70(C−4),63.06,69.07,70.97,71.01と72.95(C−3とC−5〜C−8),85.83(C−1),171.64,171.98,172.18と172.58(CH3COOとCH3CONH);−ESIHRMS計算値C18H26NO13S-:496.1130,実測値:m/z496.1142[M−H]-(160212−CJV051301).
(6b)(1S_アノマー:アキシアルスルホナート).Rf=0.39(EtOAc:EtOH=2:1);1H−NMR(600MHz,CD3OD,CJV060503):4.90−4.93(m,1H,H−1),5.81−5.84(dt,1H,J3,1=1.9,J3,2=10.1,J3,4=1.9,H−3),6.09−6.12(dt,1H,J2,1=2.9,J2,3=10.1,J2,4=2.9,H−2);−ESIHRMS計算値C16H22NO11S-:436.0919,実測値:m/z436.0928[M−H]-(160212−CJV051301).
前記で得られた化合物(5a)及び(5b)並びに化合物(6b)をモル比で約4:5:1の混合物(10mg)とし20℃で0.1M水酸化ナトリウムのメタノール溶液に懸濁し、12時間攪拌した。次に、反応液のpHを酢酸を用いて中性にし、得られた溶液を陽イオン交換樹脂(アンバーライトIR120 H)でろ過し、溶媒を減圧濃縮した。そして、残渣を高速液体クロマトグラフィー(カラム:Inertsil ODS−3セミ分取カラム10X250mm、ジーエルサイエンス社製;検出波長210nm、移動相:15%メタノール水溶液+約40mM酢酸アンモニウム、1mL/min)で精製し、化合物(7a)及び(7b)並びに化合物(8b)を得た。
(7a)(1R−アノマー、エクアトリアルスルホン酸,CJV054801).Rf=0.13(アセトン:1−ブタノール:H2O=7:2.7:0.3);1H−NMR(600MHz,CD3OD):1.76−1.82(q,1H,J2ax,1=12,J2ax,2eq=12,J2ax,3=12,H−2ax),2.00(s,3H,NAc),2.43−2.46(ddd,1H,J2eq,1=2.2Hz,J2eq,2ax=12.7,J2eq,3=4.8,H−2eq),3.46−3.47(d,1H,J=8.8,J=0.9Hz,H−6),3.62−3.65(m,2H,H−5,H−8),3.74−3.89(m,4H,H−3,H−4,H−7,H−8’),4.26−4.29(dd,1H,J1,2ax=11.7,J1,2eq=2.1HZ,H−1);−ESIHRMS計算値C10H18NO9S-:328.0708,実測値:m/z318.0724[M−H]-(160303−CJV052802).
(7b)(1S−アノマー、アキシアルスルホン酸,CJV055203,CJV060401).Rf=0.16(アセトン:1−ブタノール:H2O=7:2.7:0.3);[α]D24.8=−0.33(c=1cm、H2O);1H−NMR(600MHz,CD3OD):1.89−1.95(ddd,1H,J2ax,1=7,J2ax,2eq=14,J2ax,3=10.9,H−2ax),2.01(s,3H,NAc),2.61−2.64(ddd,1H,J2eq,1=0.7,J2eq,2ax=14,J2eq,3=5.5,H−2eq),3.43−3.45(dd,1H,J6,5=1.2,J6,7=9.1,H−6),3.57−3.60(m,1H,H−8),3.74−3.77(t,1H,J4,3=10.1,J4,5=10.1,H−4),3.79−3.84(m,2H,H−7,H−8’),4.24−4.26(dd,1H,J5,4=10.6,J5,6=1.5Hz,H−5),4.38−4.43(td,1H,J3,2ax=10.3,J3,2eq=5.4,J3,4=10.3,H−3),4.70−4.71(d,1H,J1,2ax=6.7,H−1);13C−NMR(600MHz,CDCl3):22.58(CH3CONH),34.31(C−2),54.29(C−4),64.62,67.15,70.21,72.42と74.32(C−3とC−5〜C−8),86.66(C−1),175.35(CH3CONH);−ESIHRMS計算値C10H18NO9S-:328.0708,実測値:m/z328.0725[M−H]-(160303−CJV052802).
(8b)(1S−アノマー、アキシアルスルホン酸,CJV060702).Rf=0.34(アセトン:1−ブタノール:H2O=7:2.7:0.3);1H−NMR(600MHz,CD3OD):1.9(s,3H,NAc),3.49−3.50(dd,1H,J6,5=1.5,J6,7=9.1,H−6),3.60−3.63(dd,1H,J8,7=6.2,J8,8'=11.4,H−8),3.82−3.85(dd,1H,J8',7=2.9,J8',8=11.4,H−8’),3.90−3.93(ddd,1H,J7,6=9.1,J7,8=6.2,J7,8'=2.9,H−7),4.34−4.36(dd,1H,J5,4=9.5,J5,6=1.6,H−5),4.67−4.69(dddd,1H,J4,1=2.3,J4,2=2.3,J4,3=2.3,J4,5=9.5,H−4),4.95−4.97(ddd,1H,J1,2=2.6,J1,3=2.6,J1,3=2.6,H−1),5.92−5.94(dt,1H,J3,1=2.1,J3,2=10.3,J3,4=2.1,H−3),6.12−6.14(dt,1H,J2,1=2.8,J2,3=10.3,J2,4=2.8,H−2).
NMRデータは、Agilent社製核磁気共鳴装置400MR(1H:400MHz)とNMRSystem600(1H:600MHz、13C:150MHz)で測定した。化学シフト値(δ)はppmで示し、クロロホルム(7.26ppm)及びメタノール(3.31ppm)の残存ピークを1H−NMRの基準値、クロロホルム(77.0ppm)及びメタノール(49.0ppm)の残存ピークを13C−NMRの基準値とした。NMRスピン結合定数(J)はヘルツ(Hz)で示した。
下記の表1に、本発明に係る化合物(5b)及び(7b)とホスホン酸とカルボン酸誘導体の13C−NMR化学シフトの比較を示した。表1に示すように、本発明に係るアノマー位にスルホ基が結合したシアル酸誘導体のNMR解析から、アノマー位スルホ基は、カルボキシ基及びホスホノ基よりも遥かに強力な電気誘引性(誘起)効果を示すことがわかる。すなわち、本発明に係るアノマー位にスルホ基が結合したシアル酸誘導体は、シアリダーゼを非共有結合的(静電気的、疎水性相互作用的)相互作用と同時に或いは共有結合的(可逆的及び非可逆的)相互作用を通じて阻害する。
本発明に係るシアル酸誘導体のシアリダーゼ(NA)活性の阻害について、IC50及びKi値をもって評価を行った。IC50は50%阻害濃度を示し、濃度の単位はμMである。IC50は、既に報告されている方法(例えば、Nature Communications(2013)4:1491)に基づいて蛍光を検出する方法で測定した。
Claims (7)
- 前記(B)がスルホ基であることを特徴とする請求項1又は2に記載のシアル酸誘導体。
- 請求項1〜3のいずれか1項に記載のシアル酸誘導体を有効成分とすることを特徴とするシアリダーゼ阻害剤。
- 請求項1〜3のいずれか1項に記載のシアル酸誘導体を有効成分とすることを特徴とする抗菌剤。
- 請求項1〜3のいずれか1項に記載のシアル酸誘導体を有効成分とすることを特徴とする抗ウイルス剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016162979A JP6871587B2 (ja) | 2016-08-23 | 2016-08-23 | シアル酸誘導体、その製造方法及びそれを利用したシアリダーゼ阻害剤、抗菌剤、抗ウイルス剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016162979A JP6871587B2 (ja) | 2016-08-23 | 2016-08-23 | シアル酸誘導体、その製造方法及びそれを利用したシアリダーゼ阻害剤、抗菌剤、抗ウイルス剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018030801A JP2018030801A (ja) | 2018-03-01 |
JP6871587B2 true JP6871587B2 (ja) | 2021-05-12 |
Family
ID=61304788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016162979A Active JP6871587B2 (ja) | 2016-08-23 | 2016-08-23 | シアル酸誘導体、その製造方法及びそれを利用したシアリダーゼ阻害剤、抗菌剤、抗ウイルス剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6871587B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110464729B (zh) * | 2019-08-16 | 2023-05-19 | 中国科学院昆明动物研究所 | 天然酸性糖脂分子在中和产气荚膜梭菌Epsilon毒素中的应用 |
CN114736248B (zh) * | 2022-05-06 | 2023-08-15 | 四川大学华西医院 | 一种亚磺酸盐糖基供体及其制备方法和应用 |
-
2016
- 2016-08-23 JP JP2016162979A patent/JP6871587B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018030801A (ja) | 2018-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6880127B2 (ja) | 多環式カルバモイルピリドン化合物の合成 | |
EP2417144B1 (en) | Synthesis of 2'-o-fucosyllactose | |
JP6871587B2 (ja) | シアル酸誘導体、その製造方法及びそれを利用したシアリダーゼ阻害剤、抗菌剤、抗ウイルス剤 | |
Sun et al. | An improved P (V)-N activation strategy for the synthesis of nucleoside diphosphate 6-deoxy-l-sugars | |
Ruiz et al. | Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl] adenine | |
EP0214708B1 (en) | Griseolic acid derivatives, their preparation and their use | |
JP3648740B2 (ja) | 7位をフッ素で置換した2,3−ジデヒドロシアル酸およびその合成中間体 | |
Goto et al. | Rapid oligosaccharide synthesis on a fluorous support | |
Bianco et al. | Synthesis of a carbocyclic sialic acid analogue for the inhibition of influenza virus neuraminidase | |
Allevi et al. | Two procedures for the syntheses of labeled sialic acids and their 1, 7-lactones | |
Rota et al. | Straightforward access to 2, 3-and 3, 4-unsaturated derivatives of N-glycolylneuraminic acid | |
Alauddin et al. | Synthesis of [18F]‐labeled adenosine analogues as potential PET imaging agents | |
JP4253858B2 (ja) | フラーレン誘導体およびその製造方法 | |
KR20090082506A (ko) | 이당류 화합물의 나트륨염 및 그의 제조 방법 및 그의 사용 | |
CN112457363B (zh) | 一种马铃薯三糖齐墩果酸皂苷衍生物及其制备方法和应用 | |
Streicher et al. | Synthesis of l-xylose derived cyclohexenephosphonates—versatile precursors of sialidase inhibitor libraries | |
IL189801A (en) | Process for production of lipid a analogue | |
CN115518058A (zh) | N-环烷基取代的芳甲胺类化合物在制备抗病毒药物中的用途及结构和制备方法 | |
Colombo et al. | New 6-amino-6-deoxy-glycoglycerolipids derived from 2-O-β-d-glucopyranosylglycerol: insights into the structure–activity relationship of glycoglycerolipids as anti-tumor promoters | |
Alexandrova | 4′-C-nucleoside derivatives: Synthesis and antiviral properties | |
Rodríguez-Alvarado et al. | Design, organocatalytic synthesis, and bioactivity evaluation of enantiopure fluorinated LpxC inhibitors | |
Arewång et al. | Synthesis of urine drug metabolites: glucuronic acid glycosides of phenol intermediates | |
Bianco et al. | Design and synthesis of a new furanosic sialylmimetic as a potential influenza neuraminidase viral inhibitor | |
Venditti et al. | Semi-synthesis of three precursors of carbocyclic nucleoside analogues | |
Riedl | Contributions toward the synthesis of bioactive compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200908 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20201007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210325 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210409 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6871587 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |